Limited applications for hydroxyethyl starch: Background and alternative concepts;Anwendungsbeschränkung für Hydroxyäthylstärke: Hintergründe und alternative Konzepte

Anaesthesist

Volumn 62, Issue 8, 2013, Pages 644-655

  Rehm, M ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Blood loss; Fluid therapy; Intensive care; Kidney; Recommendations

Indexed keywords

ALBUMIN; FRESH FROZEN PLASMA; GELATIN; HETASTARCH;

ANAPHYLAXIS; ARTICLE; BLEEDING; COST BENEFIT ANALYSIS; CREUTZFELDT JAKOB DISEASE; CRYSTALLOID; EMERGENCY CARE; ERYTHROCYTE CONCENTRATE; FLUID BALANCE; HUMAN; INFUSION; INTENSIVE CARE; KIDNEY INJURY; PERIOPERATIVE PERIOD; RISK FACTOR;

EMERGENCY MEDICAL SERVICES; EUROPE; HUMANS; HYDROXYETHYL STARCH DERIVATIVES; INFUSIONS, INTRAVENOUS; INTENSIVE CARE; ISOTONIC SOLUTIONS; PERIOPERATIVE CARE; PHARMACOVIGILANCE; PLASMA SUBSTITUTES; RISK ASSESSMENT;

EID: 84884701269     PISSN: 00032417     EISSN: 1432055X     Source Type: Journal    
DOI: 10.1007/s00101-013-2220-8     Document Type: Article

References (83)

1. Antonelli M, Sandroni C (2013) Hydroxyethyl starch for intravenous volume replacement: more harm than benefit. JAMA 309:723-724
2. Auwerda JJ, Wilson JH, Sonneveld P (2002) Foamy macrophage syndrome due to hydroxyethyl starch replacement: a severe side effect in plasmapheresis. Ann Intern Med 137:1013-1014
3. Barron ME, Wilkes MM, Narvickis RJ (2004) A systematic review of the comparative safety of colloids. Arch Surg 193:552-563
4. Bayer O, Reinhart K, Sakr Y, et al. (2011) Renal effects of synthetic colloids and crystalloids in patients with severe sepsis: a prospective sequential comparison. Crit Care Med 39:1335-1342
5. Bayer O, Reinhart K, Kohl M, et al. (2012) Effects of fluid resuscitation with synthetic colloids or crystalloids alone on shock reversal, fluid balance, and patient outcomes in patients with severe sepsis: a prospective sequential analysis. Crit Care Med 40:2543-2551
6. Bellmann R, Feistritzer C, Wiedermann CJ (2012) Effect of molecular weight and substitution on tissue uptake of hydroxyethyl starch: a meta-analysis of clinical studies. Clin Pharmacokinet 51:225-236
7. Boniatti MM, Cardoso PR, Castilho RK, Vieira SR (2011) Is hyperchloremia associated with mortality in critically ill patients? A prospective cohort study. J Crit Care 26:175-179
8. Bork K (2005) Pruritus precipitated by hydroxyethyl starch: a review. Br J Dermatol 152:3-12
9. Boyd JH, Forbes J, Nakada TA, et al. (2011) Fluid resuscitation in septic shock: a positive fluid balance and elevated central venous pressure are associated with increased mortality. Crit Care Med 39:259-265
10. Brunkhorst FM, Engel C, Bloos F, et al. (2008) Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 358:125-139
11. Chappell D, Jacob M, Becker BF, et al. (2008) Expedition Glykokalyx - ein neu entdecktes "Great Barrier Reef". Anaesthesist 57:959-969
12. Chappell D, Jacob M, Hofmann-Kiefer K, et al. (2008) A rational approach to perioperative fluid management. Anesthesiology 109:723-740
13. Chappell D, Bruchelt W, Schenk W, et al. (2008) Development of spontaneous subdural hematoma and bone marrow depression after hydroxyethyl starch administration. J Pediatr 153:579-581
14. Christidis C, Mal F, Ramos J, et al. (2001) Worsening of hepatic dysfunction as a consequence of repeated hydroxyethylstarch infusions. J Hepatol 35:726-732
15. Dart AB, Mutter TC, Ruth CA, Taback SP (2010) Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function. Cochrane Database Syst Rev 1:CD007594
16. Faculty of Intensive Care Medicine, the Royal College of Anaesthetists, the Intensive Care Society and the College of Emergency Medicine. Risk benefit of HES solutions questioned by EMA. http://www.rcoa.ac.uk/news-and-bulletin/ rcoa-news-and-statements/risk-benefit-of-hes-solutions-questioned-ema
17. Feldheiser A, Pavlova V, Bonomo T, et al. (2013) Balanced crystalloid compared with balanced colloid solution using a goal-directed haemodynamic algorithm. Br J Anaesth 110:231-240
18. Finfer S (2012) Hydroxyethyl starch in patients with trauma. Br J Anaesth 108:159-160
19. Finfer S, Bellomo R, Boyce N, et al. (2004) A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 350:2247-2256
20. Fries D, Hasibeder W, Kozek-Langenecker S, et al. (o J) Information Kompakt: Flüssigkeits- und Volumentherapie. http://www.oegari.at/web-files/ dateiarchiv/473/Information%20Kompakt%20Fl%C3%BCssigkeits- %20und%20Volumentherapie%201.1.pdf
21. Gattas DJ, Dan A, Myburgh J, et al. (2013) Fluid resuscitation with 6 % hydroxyethyl starch (130/0.4 and 130/0.42) in acutely ill patients: systematic review of effects on mortality and treatment with renal replacement therapy. Intensive Care Med 39:558-568
22. Gattas DJ, Dan A, Myburgh J, et al. (2012) Fluid resuscitation with 6 % hydroxyethyl starch (130/0.4) in acutely ill patients: an updated systematic review and meta-analysis. Anesth Analg 114:159-169
23. Grocott MP, Gan TJ (2011) Fluid resuscitation 'post Boldt': throwing out the baby with the bathwater? Br J Hosp Med (Lond) 72:306-307
24. Guidet B, Martinet O, Boulain T, et al. (2012) Assessment of hemodynamic efficacy and safety of 6 % hydroxyethylstarch 130/0.4 vs. 0.9 % NaCl fluid replacement in patients with severe sepsis: the CRYSTMAS study. Crit Care 16:R94
25. Gurbuz HA, Durukan AB, Salman N, et al. (2013) Hydroxyethyl starch 6 %, 130/0.4 vs. a balanced crystalloid solution in cardiopulmonary bypass priming: a randomized, prospective study. J Cardiothorac Surg 8:71
26. Haase N, Perner A, Hennings LI, et al. (2013) Hydroxyethyl starch 130/0.38-0.45 versus crystalloid or albumin in patients with sepsis: systematic review with meta-analysis and trial sequential analysis. BMJ 346:f839
27. Harper NJ, Dixon T, Dugué P, et al. (2009) Suspected anaphylactic reactions associated with anaesthesia. Anaesthesia 64:199-211
28. Hartog C (2013) Kommentar zum Beitrag "Sind synthetische Kolloide noch indiziert?" von Jacob M und Chappell D. Intensiv News MEDICOM. http://www.medicom.cc/medicom-de/inhalte/intensiv-news/entries/IN213/ Kommentar-zum-Beitrag-Sind-synthetische-Kolloide-noch-indiziert.php
29. Hartog CS, Brunkhorst FM, Engel C, et al. (2011) Are renal adverse effects of hydroxyethyl starches merely a consequence of their incorrect use? Wien Klin Wochenschr 123:145-155
30. Hartog CS, Reinhart K (2012) CRYSTMAS study adds to concerns about renal safety and increased mortality in sepsis patients. Crit Care 16:454
31. Hartog CS, Welte T, Schlattmann P, Reinhart K (2013) Volumentherapie mit Hydroxyäthylstärke beim kritisch kranken: eine Neubewertung. Dtsch Arztebl 26:451-459
32. Jacob M, Chappell D (2013) Nach VISEP, CHEST, 6S und. Sind synthetische Kolloide noch indiziert? JA - wir benötigen weiterhin künstliche Kolloide, wenn. Intensiv News MEDICOM. http://www.medicom.cc/medicom-de/inhalte/ intensiv-news/entries/IN113/Pro-Nach-VISEP-CHEST-6S-und-Sind-synthetische- Kolloide-noch-indiziert.php
33. Jacob M, Chappell D (2013) Ein Plädoyer für die Ehrlichkeit - Antwort auf den Kommentar von PD Hartog und Prof. Reinhart. Intensiv News MEDICOM. http://www.medicom.cc/medicom-de/inhalte/intensiv-news/entries/IN313/7- Ein-Plaedoyer-fuer-die-Ehrlichkeit.php
34. Jacob M, Chappell D, Hofmann-Kiefer K, et al. (2012) The intravascular volume effect of Ringer's lactate is below 20 %: a prospective study in humans. Crit Care 16:R86
35. Jacob M, Chappell D, Hofmann-Kiefer K, et al. (2007) Determinants of insensible fluid loss. Perspiration, protein shift and endothelial glycocalyx. Anaesthesist 56:747-758, 760-764
36. Jacob M, Chappell D, Conzen P, et al. (2008) Small-volume resuscitation with hyperoncotic albumin: a systematic review of randomized clinical trials. Crit Care 12:R34
37. Jacob M, Chappell D, Rehm M (2007) Clinical update: perioperative fluid management. Lancet 369:1984-1986
38. Jacob M, Rehm M, Orth V, et al. (2003) Exact measurement of the volume effect of 6 % hydoxyethyl starch 130/0.4 (Voluven) during acute preoperative normovolemic hemodilution. Anaesthesist 52:896-904
39. James MF, Michell WL, Joubert IA, et al. (2011) Resuscitation with hydroxyethyl starch improves renal function and lactate clearance in penetrating trauma in a randomized controlled study: the FIRST trial (Fluids in Resuscitation of Severe Trauma). Br J Anaesth 107:693-702
40. Joannidis M (2013) Nach VISEP, CHEST, 6S und. Sind synthetische Kolloide noch indiziert? NEIN - wir brauchen keine künstlichen Kolloide mehr! Intensiv News MEDICOM. http://www.medicom.cc/medicom-at/inhalte/intensiv-news/ entries/IN113/Contra-Nach-VISEP-CHEST-6S.php
41. Kozek-Langenecker SA, Afshari A, Albaladejo P, et al. (2013) Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol 30:270-382
42. Laubenthal H (1997) BSE und Heparin- bzw. Gelatinepräparate. Anaesthesist 46:253-254
43. Laxenaire MC, Charpentier C, Feldman L (1994) Anaphylactoid reactions to colloid plasma substitutes: incidence, risk factors, mechanisms. A French prospective multicentre enquiry. Ann Fr Anaesth Réanim 13:301-310
44. Levick JR (2004) Revision of the Starling principle: new views of tissue fluid balance. J Physiol 557:704
45. Lukasewitz P, Kroh U, Löwenstein O, et al. (1998) Quantitative Untersuchungen zur Gewebespeicherung von mittelmolekularer Hydroxyä thylstärke 200/0,5 bei Patienten mit Multiorganversagen. Anaesth Intensivmed 5:42-46
46. McCluskey SA, Karkouti K, Wijeysundera D, et al. (2013) Hyperchloremia after noncardiac surgery is independently associated with increased morbidity and mortality: a propensity-matched cohort study. Anesth Analg 17:412-421
47. Martin C, Jacob M, Vicaut E, et al. (2013) Effect of Waxy Maize-derived hydroxyethyl starch 130/0.4 on renal function in surgical patients. Anesthesiology 118:387-394
48. Metze D, Reimann S, Szepfalusi Z, et al. (1997) Persistent pruritus after hydroxyethyl starch infusion therapy: a result of long-term storage in cutaneous nerves. Br J Dermatol 136:553-559
49. Mayor S (2013) Exclusion of suspect data raises question mark over safety of common plasma substitute. BMJ 346:f1132
50. Myburgh JA, Finfer S, Bellomo R, et al. (2012) Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med 367:1901-1911
51. Navickis RJ, Haynes GR, Wilkes MM (2012) Effect of hydroxyethyl starch on bleeding after cardiopulmonary bypass: a meta-analysis of randomized trials. J Thorac Cardiovasc Surg 144:223-230
52. Patel A, Waheed U, Brett SJ (2013) Randomised trials of 6 % tetrastarch (hydroxyethyl starch 130/0.4 or 0.42) for severe sepsis reporting mortality: systematic review and meta-analysis. Intensive Care Med 39:811-822
53. Perel P, Roberts I, Ker K (2013) Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev 2:CD000567
54. Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin (2011) Muss der klinische Einsatz moderner Hydroxyethylstärke-Lösungen gegenwärtig neu bewertet werden? Stellungnahme des Präsidiums der DGAI vom 21.02.2011. Anaesth Intensivmed 52:172-173
55. Perner A, Haase N, Guttormsen AB, et al. (2012) Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. N Engl J Med 367:124-134
56. Pries AR, Secomb TW, Gaehtgens P (2000) The endothelial surface layer. Pflugers Arch 440:653-666
57. Rehm M, Conzen PF, Peter K, Finsterer U (2004) The Stewart model. "Modern" approach to the interpretation of the acid-base metabolism. Anaesthesist 53:347-357
58. Rehm M, Haller M, Brechtelsbauer H, et al. (1998) Extra protein loss not caused by surgical bleeding in patients with ovarian cancer. Acta Anaesthesiol Scand 42:39-46
59. Rehm M, Haller M, Orth V, et al. (2001) Changes in blood volume and hematocrit during acute preoperative volume loading with 5 % albumin or 6 % hetastarch solutions in patients before radical hysterectomy. Anesthesiology 95:849-856
60. Rehm M, Orth V, Kreimeier U, et al. (2000) Changes in intravascular volume during acute normovolemic hemodilution and intraoperative retransfusion in patients with radical hysterectomy. Anesthesiology 92:657-664
61. Rehm M, Orth VH, Kreimeier U, et al. (2001) Changes in blood volume during acute normovolemic hemodilution with 5 % albumin or 6 % hydroxyethylstarch and intraoperative retransfusion. Anaesthesist 50:569-579
62. Rehm M, Paptistella M, Dieterich H-J (2013) Volumenersatzlösungen. In: Roissaint, Werner, Zwißler (Hrsg) 3. Aufl. Springer, Berlin Heidelberg New York Tokio
63. Rehm M, Zahler S, Lotsch M, et al. (2004) Endothelial glycocalyx as an additional barrier determining extravasation of 6 % hydroxyethyl starch or 5 % albumin solutions in the coronary vascular bed. Anesthesiology 100:1211-1223
64. Reinhart K, Brunkhorst FM, Engel C, et al. (2008) Study protocol of the VISEP study. Response of the SepNet study group. Anaesthesist 57:723-728
65. Reinhart K, Hartog CS (2012) Hydroxyethyl starch in patients with trauma. Br J Anaesth 108:321-322
66. Schabinski F, Oishi J, Tuche F, et al. (2009) Effects of a predominantly hydroxyethyl starch (HES)-based and a predominantly non HES-based fluid therapy on renal function in surgical ICU patients. Intensive Care Med 35:1539-1547
67. Schmidt-Hieber M, Loddenkemper C, Schwartz S, et al. (2006) Hydrops lysosomalis generalisatus - an underestimated side effect of hydroxyethyl starch therapy? Eur J Haematol 77:83-85
68. Schortgen F, Lacherade JC, Bruneel F, et al. (2001) Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study. Lancet 357:911-916
69. Shaw AD, Kellum JA (2013) The risk of AKI in patients treated with intravenous solutions containing hydroxyethyl starch. Clin J Am Soc Nephrol 8:497-503
70. Ständer S, Szépfalusi Z, Bohle B (2001) Differential storage of hydroxyethyl starch (HES) in the skin: an immunoelectron-microscopical longterm study. Cell Tissue Res 304:261-269
71. Thomas-Rueddel DO, Vlasakov V, Reinhart K, et al. (2012) Safety of gelatin for volume resuscitation - a systematic review and meta-analysis. Intensive Care Med 38:1134-1142
72. Van Der Linden P, James M, Mythen M, Weiskopf RB (2013) Safety of modern starches used during surgery. Anesth Analg 116:35-48
73. Waitzinger J, Bepperling F, Pabst G, et al. (1998) Pharmacokinetics and tolerability of a new Hydroxyethyl Starch (HES) specification [HES (130/0.4)] after single-dose infusion of 6 % or 10 % solutions in healthy volunteers. Clin Drug Investig 16:151-160
74. Wiedermann CJ, Joannidis M (2013) Increased mortality after infusion of "modern" hydroxyethyl starch. Swiss Med Wkly 143:w13747
75. Wiedermann CJ, Joannidis M (2012) Mortality after hydroxyethyl starch 130/0.4 infusion: an updated meta-analysis of randomized trials. Swiss Med Wkly 142:w1365
76. Wiedermann CJ, Dunzendorfer S, Gaioni LU, et al. (2010) Hyperoncotic colloids and acute kidney injury: a meta-analysis of randomized trials. Crit Care 14:R191
77. Winstedt D, Hanna J, Schött U (2013) Albumin-induced coagulopathy is less severe and more effectively reversed with fibrinogen concentrate than is synthetic colloid-induced coagulopathy. Scand J Clin Lab Invest 73:161-169
78. Wise J (2013) Boldt: the great pretender. BMJ 346:f1738
79. Yunos NM, Bellomo R, Hegarty C, et al. (2012) Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults. JAMA 308:1566-1572
80. Zander R, Boldt J, Engelmann L, et al. (2007) Studienprotokoll der VISEP-Studie Eine kritische Stellungnahme. Anaesthesist 56:71-77
81. Zampieri FG, Ranzani OT, Morato PF, et al. (2013) Effect of intraoperative HES 6 % 130/0.4 on the need for blood transfusion after major oncologic surgery: a propensity-matched analysis. Clinics (Sao Paulo) 68:501-509
82. Zarychanski R, Abou-Setta AM, Turgeon AF, et al. (2013) Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and meta-analysis. JAMA 309:678-688
83. Mutter TC, Ruth CA, Dart AB (2013) Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function. Cochrane Database Syst Rev 7:CD007594